Akanda Corp. Regains Nasdaq Compliance, Resolving Delisting Risk
AKAN has more than doubled off its 52-week low of $2.295.
Summary
Akanda Corp. has regained compliance with Nasdaq's periodic filing requirement by submitting its 2025 Annual Report, thereby resolving the previously announced delisting risk.
Key Events · Corporate Governance and Compliance · AKAN
-
Regains Nasdaq Compliance
Akanda Corp. received written notice from Nasdaq confirming it has regained compliance with Listing Rule 5250(c)(1) by timely filing its 2025 Annual Report on Form 20-F.
-
Resolves Delisting Threat
This action closes the matter regarding the potential delisting risk previously announced on May 20, 2026, due to the late filing of the annual report.
Analysis · AKAN · Life Sciences
This filing confirms Akanda Corp. has resolved its non-compliance with Nasdaq's periodic filing rule by submitting its 2025 Annual Report on Form 20-F. This removes the immediate threat of delisting, which was disclosed on May 22, 2026, and is a crucial step in maintaining its public listing and investor confidence.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $15.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.